Comparative Pharmacology
Head-to-head clinical analysis: CLEOCIN PHOSPHATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus CLINDAMYCIN PHOSPHATE IN 5 DEXTROSE IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLEOCIN PHOSPHATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus CLINDAMYCIN PHOSPHATE IN 5 DEXTROSE IN PLASTIC CONTAINER.
CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER vs CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clindamycin phosphate is a prodrug that is hydrolyzed to clindamycin, which reversibly binds to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis by blocking peptide bond formation. It exhibits primarily bacteriostatic activity against susceptible gram-positive cocci and anaerobes.
Clindamycin phosphate is a prodrug that is hydrolyzed to clindamycin, a lincosamide antibiotic. It reversibly binds to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis by blocking peptide bond formation. It exhibits bacteriostatic activity against susceptible organisms.
Clindamycin 600-2700 mg/day IV divided every 6-8 hours. For severe infections, up to 4800 mg/day IV may be given.
1200-2700 mg/day IV divided every 6-12 hours; typical adult dose: 600-900 mg IV every 8 hours.
None Documented
None Documented
The terminal elimination half-life is approximately 2.4-3.0 hours in adults with normal renal and hepatic function; prolonged to 3-6 hours in hepatic impairment and up to 8-14 hours in severe hepatic disease.
Terminal elimination half-life is 2-4 hours in adults with normal hepatic and renal function. In patients with severe hepatic impairment, half-life may increase to 8-12 hours. Renal impairment generally does not significantly alter half-life. In neonates, half-life ranges from 8-20 hours depending on gestational age.
Clindamycin is primarily eliminated via hepatic metabolism; approximately 10% is excreted unchanged in urine, 3.6% in feces, and the remainder as inactive metabolites in bile and urine.
Approximately 10% of the administered dose is excreted unchanged in urine via glomerular filtration; about 90% is metabolized hepatically to inactive metabolites, which are excreted in bile and feces. Biliary excretion accounts for approximately 80% of total elimination, with enterohepatic recirculation.
Category C
Category A/B
Lincosamide Antibiotic
Lincosamide Antibiotic